Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins
Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins
Company Info
Company news
Tue, 23 Jan 2024 08:00:00 GMT
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies - PR Newswire
Thu, 12 Dec 2024 08:00:00 GMT
The Escalator: Biogen, Accent Therapeutics, Xira Therapeutics and more - MM+M Online
Mon, 18 Oct 2021 07:00:00 GMT
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 - Business Wire
Thu, 24 Oct 2024 07:00:00 GMT
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor - PR Newswire
Mon, 08 Apr 2024 07:00:00 GMT
Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting - PR Newswire
Fri, 18 May 2018 07:00:00 GMT
Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins - Business Wire
Wed, 11 Dec 2024 08:00:00 GMT
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition - PR Newswire
Thu, 21 Mar 2024 07:00:00 GMT
Accent Therapeutics to Present Data Supporting DHX9 and KIF18A as Compelling Therapeutic Targets at American Association for Cancer Research (AACR) Annual Meeting 2024 - PR Newswire
Tue, 10 Oct 2023 07:00:00 GMT
Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium - PR Newswire
Sun, 16 Apr 2023 07:00:00 GMT
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 - PR Newswire
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.
Related people
JH
SH
SH
SH